Lv71
5000 积分 2022-08-11 加入
Unlocking the potential of bispecific ADCs for targeted cancer therapy
1个月前
已完结
How antibody–drug conjugates aim to take down cancer
1个月前
已完结
Exploring the next generation of antibody–drug conjugates
1个月前
已完结
Dual-payload Antibody–drug Conjugates: Taking a Dual Shot
1个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
1个月前
已完结
PERSONALIZED MEDICINE IN ORAL CANCER
1个月前
已完结
PDX models for functional precision oncology and discovery science
1个月前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
3个月前
已完结
[Introduction to the 9
3个月前
已完结
41 (PB029): Preclinical characterization of ABSK131, a potential best-in-class MTAcooperative PRMT5 inhibitor
4个月前
已关闭
皖公网安备34019202002308
